Post by
etcetera on Apr 29, 2020 9:54am
No CARDIOTOXICITY
Mariusz Olejniczak, CEO of WPD commented,
"As Annamycin continues to advance, and studies so far have demonstrated the absence of any cardiotoxicity,
we believe the trial can and should move more aggressively to establish the maximum tolerated dose, or MTD.
The URPL authorization now sets the stage to accelerate the dose escalation process.
Even though we've seen promising activity from Annamycin, the dosing levels may be still sub-therapeutic.
Based on prior clinical experience with Annamycin, the 300 mg/m2 dosing level will be the first opportunity to test Annamycin at what we expect will be therapeutic levels."